Drug Information

Drug General Information
Drug ID
D0P2GK
Former ID
DIB012588
Drug Name
Sodium phenylbutyrate
Synonyms
Ammonaps; Buphenyl; EL-532; Sodium 4-phenylbutyrate; Sodium phenylbutyrate, Elan; Sodium phenylbutyrate, Medicis; Sodium phenylbutyrate, Ucyclyd; VP-101; Sodium 4-phenylbutyrate, Elan; Sodium 4-phenylbutyrate, Ucyclyd; Sodium phenylbutyrate (cancer), MacroChem/Access; Sodium phenylbutyrate (cancer), Virium/ Somanta; Sodium phenylbutyrate (cancer), Virium/Access Pharmaceuticals; Sodium 4-phenyibutyrate (cancer), MacroChem/Access; Sodium 4-phenylbutyrate (cancer), Virium/ Somanta; Sodium 4-phenylbutyrate (cancer), Virium/Access Pharmaceuticals
Drug Type
Small molecular drug
Indication Spinal muscular atrophy [ICD9: 335.0-335.1; ICD10:G00-G99] Approved [522122]
Company
Ucyclyd Pharma Inc; Elan Corp plc
Structure
Download
2D MOL

3D MOL
Formula
C10H11NaO2
Canonical SMILES
c1(CCCC(=O)[O-])ccccc1.[Na+]
CAS Number
CAS 1716-12-7
PubChem Compound ID
5258
Target and Pathway
Target(s) Histone deacetylase Target Info Inhibitor [530995], [551871]
References
Ref 522122ClinicalTrials.gov (NCT00533559) Mechanism of Fatty Acid-induced Impairment of Glucose-simulated Insulin Secretion - Effect of Buphenyl. U.S. National Institutes of Health.
Ref 530995Histone Deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases. Curr Drug Targets. 2010 Nov;11(11):1430-8.
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.